Language: BG BG
nav.cta
← Back to results
Recruiting Phase 3 2025-521711-39-00

A 52-Week, Phase 3, Open-Label Extension Study of ACP-204 in Adults With Lewy Body Dementia Psychosis (LBDP)

Phase 3 – large-scale trial before approval
Conditions: Lewy body Dementia psychosis (LBDP)

Sponsor: Acadia Pharmaceuticals Inc.

trial.available_in: БГ
Overview
Trial status: Authorised Treatment-emergent adverse events (TEAEs)
Who can participate
Age group: 65+ years, 18-64 years Gender: Female, Male Target enrollment: 49 participants
Locations 4
Bulgaria (1)
Czech Republic (1)
France (1)
Italy (1)
Technical details
Status
Recruiting
Phase
Phase 3
Study type
INTERVENTIONAL
Sex
Male and female
Minimum age
18 Years
Healthy volunteers
No
Start date
03.11.2025
Registry ID
2025-521711-39-00
Source
euclinicaltrials.eu
trial.inquiry_btn

Information is automatically extracted from ClinicalTrials.gov. Consult your doctor before taking action.